Positive Outlook for Gain Therapeutics: Promising Clinical Trial Results and Stable Financial Health Drive Buy Rating
I'm PortAI, I can summarize articles.
BTIG analyst Thomas Shrader maintains a Buy rating on Gain Therapeutics (GANX) due to promising clinical trial results for their drug GT-02287, which shows potential in treating Parkinson’s disease. The drug is well tolerated, with positive patient reception. Upcoming biomarker data may further validate its efficacy. Financially, the company is stable, with growth potential indicated by a discounted cash flow analysis. Roth MKM also reiterates a Buy rating with a $6.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments